{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=27",
    "query": {
      "intervention": "Placebo once daily",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 5498,
    "total_pages": 550,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T10:52:51.751Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01423916",
      "title": "Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "OPC-34712 (4mg)",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "OPC-34712 (12mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 218,
      "start_date": "2011-07",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2015-10-29",
      "last_synced_at": "2026-10-17T10:52:51.751Z",
      "location_count": 8,
      "location_summary": "Long Beach, California • San Diego, California • Fort Lauderdale, Florida + 5 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01423916"
    },
    {
      "nct_id": "NCT03720470",
      "title": "Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dermatitis",
        "Dermatitis, Atopic",
        "Eczema",
        "Skin Diseases",
        "Skin Diseases, Genetic",
        "Genetic Diseases, Inborn",
        "Skin Diseases, Eczematous",
        "Hypersensitivity",
        "Hypersensitivity, Immediate",
        "Immune System Diseases"
      ],
      "interventions": [
        {
          "name": "PF-04965842 100 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-04965842 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        },
        {
          "name": "Injectable Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 838,
      "start_date": "2018-10-29",
      "completion_date": "2020-03-06",
      "has_results": true,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-10-17T10:52:51.751Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03720470"
    },
    {
      "nct_id": "NCT00362869",
      "title": "Enteroaggregative E.Coli (EAEC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Escherichia Coli Infections"
      ],
      "interventions": [
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Enteroaggregative E. coli (EAEC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 5,
      "start_date": "2008-02",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-26",
      "last_synced_at": "2026-10-17T10:52:51.751Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362869"
    },
    {
      "nct_id": "NCT00455429",
      "title": "An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "JNJ-26113100 (50 mg) once daily",
          "type": "DRUG"
        },
        {
          "name": "JNJ-26113100 (100 mg) once daily",
          "type": "DRUG"
        },
        {
          "name": "JNJ-26113100 (100 mg) twice daily",
          "type": "DRUG"
        },
        {
          "name": "JNJ-26113100 (250 mg) twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 84,
      "start_date": "2007-04",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2014-03-12",
      "last_synced_at": "2026-10-17T10:52:51.751Z",
      "location_count": 19,
      "location_summary": "Huntsville, Alabama • Los Angeles, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00455429"
    },
    {
      "nct_id": "NCT01437787",
      "title": "Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hematopoietic Neoplasm"
      ],
      "interventions": [
        {
          "name": "SAR302503",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 289,
      "start_date": "2011-12-31",
      "completion_date": "2014-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-17T10:52:51.751Z",
      "location_count": 9,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01437787"
    },
    {
      "nct_id": "NCT01064687",
      "title": "A Study in Participants With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "LY2189265",
          "type": "DRUG"
        },
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 978,
      "start_date": "2010-02",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2015-01-26",
      "last_synced_at": "2026-10-17T10:52:51.751Z",
      "location_count": 78,
      "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cathedral City",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01064687"
    },
    {
      "nct_id": "NCT02204371",
      "title": "Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Telangiectasia, Hereditary Hemorrhagic"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 7,
      "start_date": "2015-02-25",
      "completion_date": "2016-02-10",
      "has_results": true,
      "last_update_posted_date": "2017-07-06",
      "last_synced_at": "2026-10-17T10:52:51.751Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02204371"
    },
    {
      "nct_id": "NCT01628393",
      "title": "Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 258,
      "start_date": "2012-09-18",
      "completion_date": "2016-05-11",
      "has_results": true,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-10-17T10:52:51.751Z",
      "location_count": 6,
      "location_summary": "Berkeley, California • Fresno, California • Sacramento, California + 3 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01628393"
    },
    {
      "nct_id": "NCT01231516",
      "title": "A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK1349572",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "GSK1349572 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 724,
      "start_date": "2010-10-26",
      "completion_date": "2021-02-02",
      "has_results": true,
      "last_update_posted_date": "2022-03-15",
      "last_synced_at": "2026-10-17T10:52:51.751Z",
      "location_count": 68,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231516"
    },
    {
      "nct_id": "NCT04137107",
      "title": "Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Stage II Colorectal Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2020-06-17",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-10-17T10:52:51.751Z",
      "location_count": 792,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 525 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04137107"
    }
  ]
}